Doctor Mason Freeman
CinCor Pharma, Boston (United States of America)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107
Event: ESC Congress 2022
Topic: Pharmacotherapy
Session: Hypertension - Pharmacotherapy
ESC 365 is supported by
